Different molecular mechanisms can lead to loss of TFPI-2 expression in cancer, including deletions, mutations in the promoter (41) and epigenetic silencing (55), and recent evidence indicates that TFPI-2 can also be downregulated by miR-616 in prostate cancer (56). Here, TFPI2 is linked to prostate cancer.